Home - Boston Life Sciences Times

Neurosterix Raises $105 Million in Series B Financing, Names Three Neuropsychiatry Drug Development Leaders

November 12, 2026

Massachusetts Jury Awards $3.3 Million in Mesothelioma Case Against Johnson & Johnson

November 10, 2026

Viridian Therapeutics Reports Positive Phase 1 Results for VRDN-008, Plans Myasthenia Gravis Trial in 2027

November 9, 2026

THIS WEEK'S STORIES

Nimbus Therapeutics Begins Phase 1 Trial of SIK2 Inhibitor for Inflammatory Diseases

November 10, 2026

Oyster Therapeutics Raises $60 Million to Advance Alzheimer’s Drug Development, Partners With Massachusetts General Hospital

November 10, 2026

Alnylam and Regeneron Report Up to 80% Reduction in Liver Fat With Experimental RNAi Treatment

November 10, 2026

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Most Popular

Kardigan Reports $591.4 Million Cash Position as Cardiovascular Drug Trials Advance

KalVista Presents New Research on Hereditary Angioedema Treatment at ACAAI Annual Meeting

enGene Reports Improved Bladder Cancer Trial Results, Plans FDA Submission by Year-End

a2z Radiology AI Secures EU Certification for AI Software Detecting 182 CT Scan Findings

Recent Comments

EDITOR PICKS

Neurosterix Raises $105 Million in Series B Financing, Names Three Neuropsychiatry Drug Development Leaders

Massachusetts Jury Awards $3.3 Million in Mesothelioma Case Against Johnson & Johnson

Viridian Therapeutics Reports Positive Phase 1 Results for VRDN-008, Plans Myasthenia Gravis Trial in 2027

THIS WEEK'S STORIES

Nimbus Therapeutics Begins Phase 1 Trial of SIK2 Inhibitor for Inflammatory Diseases

Oyster Therapeutics Raises $60 Million to Advance Alzheimer’s Drug Development, Partners With Massachusetts General Hospital

Alnylam and Regeneron Report Up to 80% Reduction in Liver Fat With Experimental RNAi Treatment

POPULAR CATEGORY

ABOUT US

FOLLOW US

LATEST ARTICLES

Most Popular

Recent Comments

EDITOR PICKS

THIS WEEK'S STORIES

POPULAR CATEGORY

ABOUT US

FOLLOW US